Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Significance: Acute myeloid leukemia (AML) is a hematologic malignancy with poor survival. Current treatment with chemotherapy does not target the leukemic cells specifically and is associated with severe side effects. Here we demonstrate that antibodies directed at the cell surface molecule IL-1 receptor accessory protein (IL1RAP), expressed on immature AML cells, show strong antileukemic effects in mice transplanted with human AML cells and that the mechanism behind the cell killing is through recruitment of effector cells. Using antibodies against IL1RAP also capable of blocking IL-1 signaling, we show that the proliferation of human AML cells can be inhibited, providing a second mode of action of IL1RAP antibodies. These results provide critical evidence in support of a rapid clinical development of an antibody-based anti-IL1RAP therapy in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Wunderlich, M., Chou, F.-S., Link, K. A., Mizukawa, B., Perry, R. L., Carroll, M., & Mulloy, J. C. (2010) · Leukemia · doi:10.1038/leu.2010.158 · Cited by 415
Self-citationBarreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Rambaldi, A., Torcia, M., Bettoni, S., Vannier, E., Barbui, T., Shaw, A., Dinarello, C., & Cozzolino, F. (1991) · Blood · doi:10.1182/blood.v78.12.3248.3248 · Cited by 129
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T. (2013) · Blood · doi:10.1182/blood-2012-09-458935 · Cited by 127
Self-citation
Cited by
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Biology and relevance of human acute myeloid leukemia stem cells
Thomas, D., & Majeti, R. (2017) · Blood · doi:10.1182/blood-2016-10-696054 · Cited by 500
The family of the interleukin‐1 receptors
Boraschi, D., Italiani, P., Weil, S., & Martin, M. U. (2018) · Immunological Reviews · doi:10.1111/imr.12606 · Cited by 389
Chronic immune response dysregulation in MDS pathogenesis
Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226
Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
Self-citation
Metadata
- Authors
- Ågerstam, H., Karlsson, C., Hansen, N., Sandén, C., Askmyr, M., von Palffy, S., Högberg, C., Rissler, M., Wunderlich, M., Juliusson, G., Richter, J., Sjöström, K., Bhatia, R., Mulloy, J. C., Järås, M., & Fioretos, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-08-10
- Volume
- 112
- Issue
- 34
- Pages
- 10786-10791
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1915464687
- Cited by
- 111
- References
- 9
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. https://app.cochat.ai/papers/10.1073/pnas.1422749112
- The paper
- Ågerstam, H., Karlsson, C., Hansen, N., Sandén, C., Askmyr, M., von Palffy, S., Högberg, C., Rissler, M., Wunderlich, M., Juliusson, G., Richter, J., Sjöström, K., Bhatia, R., Mulloy, J. C., Järås, M., & Fioretos, T. (2015). Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1422749112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.